OncoMatch/Clinical Trials/NCT07848828
Autonomic and Renal Contributions to Hypertension With ADT
Official title: Autonomic and Renal Contributions to Hypertension With Androgen Deprivation Therapy
Is NCT07848828 recruiting? Yes, currently enrolling (Oct 2026). This Phase 4 trial studies multiple treatments including Gonadotropin Releasing Hormone Agonists (GNRH) and Androgen receptor (AR) inhibitor for androgen deprivation therapy.
Treatment: Gonadotropin Releasing Hormone Agonists (GNRH) · Androgen receptor (AR) inhibitor — This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Demographics
Lab requirements
Kidney function
no chronic kidney disease; serum creatinine ≤1.3 mg/dL; macroalbuminuria ≤300 mg/g of proteinuria; no pre-existing or active renal disease
Liver function
no acute liver disease; no pre-existing or active hepatic disease
Cardiac function
no pre-existing or active cardiac disease; healthy as determined by medical history, physical exam, blood and urine chemistries and resting and exercise ECG during a physician supervised graded exercise treadmill test
healthy as determined by medical history, physical exam, blood and urine chemistries and resting and exercise ECG during a physician supervised graded exercise treadmill test OR recent diagnosis of non-metastatic prostate cancer with plans to undergo androgen deprivation therapy; no acute liver disease; chronic kidney disease, serum creatinine >1.3 mg/dL, macroalbuminuria >300 mg/g of proteinuria; pre-existing or active cardiac, renal or hepatic disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Virginia Commonwealth University · Richmond, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07848828 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages